[1]尹婉宜,沈 扬,张丽红,等.青黄散加解毒化瘀方治疗骨髓增生异常综合征疗效及对患者血清可溶性细胞间黏附分子-1、转化生长因子-β1的影响[J].陕西中医,2022,(8):1056-1059.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.016]
　YIN Wanyi,SHEN Yang,ZHANG Lihong,et al.Qinghuang powder and Jiedu Huayu recipe in the treatment of myelodysplastic syndromeand its effect on serum soluble intercellular adhesion molecule-1 and transforming growth factor-β1 levels[J].,2022,(8):1056-1059.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.016]
点击复制

青黄散加解毒化瘀方治疗骨髓增生异常综合征疗效及对患者血清可溶性细胞间黏附分子-1、转化生长因子-β1的影响
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2022年8期
页码:
1056-1059
栏目:
临床研究
出版日期:
2022-08-05

文章信息/Info

Title:
Qinghuang powder and Jiedu Huayu recipe in the treatment of myelodysplastic syndromeand its effect on serum soluble intercellular adhesion molecule-1 and transforming growth factor-β1 levels
作者:
尹婉宜; 沈 扬; 张丽红; 马 兵; 王建英; 杨 柳
(河北医科大学第一医院血液内科,河北 石家庄 050031)
Author(s):
YIN Wanyi; SHEN Yang; ZHANG Lihong; MA Bing; WANG Jianying; YANG Liu
(Department of Hematology,the First Hospital of Hebei Medical University,Shijiazhuang 050031,China)
关键词:
骨髓增生异常综合征;  毒瘀阻滞证;  青黄散加解毒化瘀方;  可溶性细胞间黏附分子;  转化生长因子β1
Keywords:
Myelodysplastic syndrome;  Toxin and blood stasis syndrome;  Qinghuang powder plus Jiedu Huayu recipe;  Soluble intercellular adhesion molecule;  Transforming growth factor β1
分类号:
R 551.3
DOI:
DOI:10.3969/j.issn.1000-7369.2022.08.016
文献标志码:
A
摘要:
目的: 探究青黄散加解毒化瘀方对毒瘀阻滞证骨髓增生异常综合征(MDS)的疗效及血清可溶性细胞间黏附分子(sICAM-1)、转化生长因子β1(TGF-β1)水平的影响。方法:选取76例MDS患者作为研究对象,随机分为试验组和对照组,各38例,对照组予以西医基础治疗,试验组在对照组基础上联合青黄散加解毒化瘀方治疗。两组患者均于给药4个月后评估临床疗效、中医证候积分、血常规指标水平、血清学免疫因子水平,并记录两组患者不良反应发生率。结果:治疗后两组患者的主症及次症评分均低于治疗前,且试验组均低于对照组(P<0.05)。试验组临床疗效优于对照组(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。治疗后,两组患者的血清sICAM-1水平均低于治疗前,且试验组低于对照组(P<0.05); 两组治疗后TGF-β1水平较治疗前升高,试验组高于对照组(P<0.05)。治疗后,两组PLT、Hb、WBC水平较治疗前升高,试验组PLT、Hb水平均高于对照组(P<0.05)。结论:青黄散加解毒化瘀方应用于毒瘀阻滞证MDS患者治疗中,有助于促进患者症状恢复,改善血常规指标水平,调节血清免疫因子水平,且安全性良好。
Abstract:
Objective:To explore the curative effect of Qinghuang powder plus Jiedu Huayu recipe on myelodysplastic syndrome(MDS)and the level of serum soluble intercellular adhesion molecule(sICAM-1)and transforming growth factor β1(TGF-β1)influence.Methods:76 patients with MDS were selected as the research objects.They were randomly divided into experimental group and control group,with 38 cases in each group.The control group was treated with basic western medicine,and the experimental group was treated with Qinghuang powder and Jiedu Huayu formula on the basis of the control group.The clinical efficacy,TCM syndrome score,hemogram index level and serological immune factor level of the two groups were evaluated 4 months after administration,and the incidence of adverse reactions was recorded.Results:After administration,the two group's scores of secondary and main syndromes were lower than those before treatment,the scores of the control group were higher than the experimental group(P<0.05).The clinical effect of the experimental group was better than that of the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).After treatment,the level of serum sICAM-1 in the two groups was lower than that before treatment,and that in the control group was higher than the experimental group(P<0.05).TGF-β1 in the experimental group was higher than that in the control group(P<0.05).After treatment,the levels of PLT,Hb and WBC in the two groups were higher than those before treatment,and the levels of PLT and Hb in the experimental group were higher than those in the control group(P<0.05).Conclusion:Qinghuang powder plus Jiedu Huayu recipe is used in the treatment of patients with MDS with stagnation of toxins and stasis syndrome,which helps to promote the recovery of symptoms,improve the level of blood indicators,and regulate the level of serum immune factors.It has superior clinical efficacy and good safety.

参考文献/References:

[1] 李振波,陆 诚.阿扎胞苷治疗骨髓增生异常综合征合并额外性梳样蛋白1基因突变疗效及安全性分析[J].陕西医学杂志,2021,50(9):1135-1138,1142.
[2] 高 飞,许勇钢,王洪志,等.青黄散联合健脾补肾方对骨髓增生异常综合征患者HDAC1基因去甲基化的影响[J].中国中西医结合杂志,2019,39(7):810-815.
[3] 刘艳芬,刘 欣,訾建杰,等.HAG联合地西他滨对骨髓增生异常综合征患者免疫功能的影响[J].河北医药,2021,43(8):1219-1222.
[4] 杨宇娟,王 倩,张慈现,等.地西他滨对伴有DNMT3A、TET2基因突变的老年骨髓增生异常综合征患者甲基化水平的影响[J].中国老年学杂志,2021,41(3):548-551.
[5] 张飞虎,刘金香,张晓娇,等.地西他滨对骨髓增生异常综合征患者分层治疗的疗效分析[J].国际免疫学杂志,2021,44(3):268-273.
[6] 周玉才,孙长勇,王茂生,等.参芪扶正注射液对MDS患者血清叶酸、VB12及EPO的影响[J].陕西中医,2017,38(5):605-606.
[7] 高 飞,许勇钢,王洪志,等.青黄散联合健脾方对骨髓增生异常综合征患者DACT1基因甲基化及Wnt/β-catenin通路的影响[J].中华中医药杂志,2020,35(7):3362-3366.
[8] 王德秀,麻 柔,李 柳,等.青黄散联合补肾健脾方及雄激素治疗伴原始细胞增多骨髓增生异常综合征疗效回顾性分析[J].中国中西医结合杂志,2019,39(1):33-37.
[9] 魏 征,张爱华,李亚峰,等.化瘀解毒方对胃癌上皮间质转化作用的研究[J].中国免疫学杂志,2019,35(24):3038-3041,3047.
[10] 荆向景,张明芹.健脾益髓解毒法联合雄黄对骨髓增生异常综合征患者血清sICAM-1、TGF-β1和LIF水平的影响[J].四川中医,2019,37(4):84-87.
[11] 肖志坚,郝玉书.骨髓增生异常综合征的诊断分型与预后判断及疗效标准[J].中华内科杂志,2002,41(12):846-848.
[12] 世界中医药学会联合会血液病专业技术标准审定委员会.髓毒劳(骨髓增生异常综合征)中医临床实践指南[J].国际中医中药杂志,2019,41(4):323-326.
[13] 国家食品药品监督管理总局.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:71-76.
[14] 陈 卓,鞠建庆,张 杰,等.青黄散治疗骨髓增生异常综合症的网络药理学研究[J].现代肿瘤医学,2021,29(2):292-298.
[15] 崔 雪,崔建娇,丛玉珠,等.四种检验方法不同组合对急性髓系白血病和骨髓增生异常综合征的诊断价值研究[J].陕西医学杂志,2021,50(6):738-741.
[16] 刘艳芬,刘 欣,訾建杰,等.HAG联合地西他滨对骨髓增生异常综合征患者凋亡自噬相关基因表达的影响[J].河北医药,2021,43(6):890-893.
[17] 庄红丽,文海英,杨 阳.地西他滨联合CAG治疗中危骨髓增生异常综合征患者临床分析[J].中华老年多器官疾病杂志,2021,20(9):695-696.
[18] 刘 欣,刘艳芬,孙 旭,等.血速升颗粒联合复方黄黛片治疗骨髓增生异常综合征化疗相关血细胞减少临床研究[J].陕西中医,2021,42(1):78-80.
[19] 欧田田,代兴斌,孙雪梅.中西医结合治疗骨髓增生异常综合征[J].中医学报,2020,35(7):1416-1419.
[20] 王 雪,孙长岗.青黛作用于急性幼粒细胞白血病的可视化“药靶蛋白模型”分析[J].世界中医药,2020,15(12):1692-1698,1704.

相似文献/References:

[1]刘 欣,刘艳芬,孙 旭,等.血速升颗粒联合复方黄黛片治疗骨髓增生异常综合征化疗相关血细胞减少临床研究[J].陕西中医,2021,(1):78.[doi:DOI:10.3969/j.issn.1000-7369.2020.01.020]

备注/Memo

备注/Memo:
基金项目:河北省卫生健康委员会医学科学研究项目(20200125)
更新日期/Last Update: 2022-08-10